Published in J Surg Res on October 08, 2011
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas | NCT01088815
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors | NCT01302405
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer | NCT01232829
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer | NCT01192763
Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery (2012) 3.87
Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-β/SMAD signaling. Oncogene (2013) 1.03
Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer. Br J Cancer (2015) 0.99
Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer. Front Oncol (2013) 0.98
BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. Mol Cancer Ther (2014) 0.98
Human correlates of provocative questions in pancreatic pathology. Adv Anat Pathol (2012) 0.97
GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. Sci Rep (2015) 0.97
Cancer stem cells, tumor dormancy, and metastasis. Front Endocrinol (Lausanne) (2012) 0.96
Role of epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma: is tumor budding the missing link? Front Oncol (2013) 0.95
Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma and pancreatic tumor cell lines: the role of neutrophils and neutrophil-derived elastase. Clin Dev Immunol (2012) 0.93
Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene (2013) 0.89
Snail cooperates with KrasG12D to promote pancreatic fibrosis. Mol Cancer Res (2013) 0.88
c-Met in pancreatic cancer stem cells: therapeutic implications. World J Gastroenterol (2012) 0.88
Membrane Type 1 Matrix Metalloproteinase induces an epithelial to mesenchymal transition and cancer stem cell-like properties in SCC9 cells. BMC Cancer (2013) 0.83
Cancer Stem Cells and Macrophages: Implications in Tumor Biology and Therapeutic Strategies. Mediators Inflamm (2016) 0.83
Rare long-term survivors of pancreatic adenocarcinoma without curative resection. World J Gastroenterol (2015) 0.82
Novel regulatory program for norepinephrine-induced epithelial-mesenchymal transition in gastric adenocarcinoma cell lines. Cancer Sci (2014) 0.81
The tumor microenvironment: An irreplaceable element of tumor budding and epithelial-mesenchymal transition-mediated cancer metastasis. Cell Adh Migr (2016) 0.80
Akt-mediated transforming growth factor-β1-induced epithelial-mesenchymal transition in cultured human esophageal squamous cancer cells. Cancer Gene Ther (2014) 0.80
Snail cooperates with Kras G12D in vivo to increase stem cell factor and enhance mast cell infiltration. Mol Cancer Res (2014) 0.80
SIBLINGs and SPARC families: their emerging roles in pancreatic cancer. World J Gastroenterol (2014) 0.80
S100 calcium-binding protein A6 promotes epithelial-mesenchymal transition through β-catenin in pancreatic cancer cell line. PLoS One (2015) 0.78
Joint network and node selection for pathway-based genomic data analysis. Bioinformatics (2013) 0.77
ETS-Transcription Factor ETV1 Regulates Stromal Expansion and Metastasis in Pancreatic Cancer. Gastroenterology (2016) 0.77
Differential Regulation of ZEB1 and EMT by MAPK-Interacting Protein Kinases (MNK) and eIF4E in Pancreatic Cancer. Mol Cancer Res (2015) 0.77
The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical Significance. J Clin Med (2017) 0.75
Slug inhibits pancreatic cancer initiation by blocking Kras-induced acinar-ductal metaplasia. Sci Rep (2016) 0.75
Role of histone deacetylases in pancreas: Implications for pathogenesis and therapy. World J Gastrointest Oncol (2015) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 48.95
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82
Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell (2003) 25.94
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol (2008) 24.27
Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature (2003) 20.48
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Identification of pancreatic cancer stem cells. Cancer Res (2007) 18.36
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev (2008) 15.01
Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res (2005) 13.89
Pancreatic cancer. N Engl J Med (2010) 13.88
Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell (2009) 12.96
Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A (2007) 11.94
TGF-beta signaling in tumor suppression and cancer progression. Nat Genet (2001) 11.64
The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 11.16
A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep (2008) 10.71
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature (2003) 10.33
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One (2008) 8.97
How cells read TGF-beta signals. Nat Rev Mol Cell Biol (2000) 8.93
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol (2009) 8.63
Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell (2009) 8.33
A paracrine requirement for hedgehog signalling in cancer. Nature (2008) 8.16
Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature (2003) 8.14
Gene silencing in mammals by small interfering RNAs. Nat Rev Genet (2002) 7.80
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg (2006) 7.18
A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell (2009) 6.23
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev (2006) 5.53
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res (2007) 5.12
Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov (2010) 4.25
Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res (2009) 4.24
Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci U S A (2008) 4.20
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res (2009) 4.19
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle (2009) 3.68
The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res (2005) 3.65
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res (2009) 3.57
Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res (2008) 3.41
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30
Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells (2009) 3.25
Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology (2010) 3.10
Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet (2009) 3.09
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst (2010) 3.08
Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med (2007) 3.05
Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res (2007) 2.92
CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest (2011) 2.90
MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg (2008) 2.86
Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer (2007) 2.85
Snail activation disrupts tissue homeostasis and induces fibrosis in the adult kidney. EMBO J (2006) 2.80
Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice. Gastroenterology (2010) 2.73
Transcriptional crosstalk between TGF-β and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle (2010) 2.61
Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med (2009) 2.60
Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res (2010) 2.50
Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res (2010) 2.43
Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res (2009) 2.40
High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res (2010) 2.39
Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell (2007) 2.36
CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer (2009) 2.33
A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell Biochem (2007) 2.32
The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J (2011) 2.29
Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology (2009) 2.25
Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology (2009) 2.17
Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther (2007) 2.07
Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res (2009) 2.03
Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res (2006) 1.99
Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle (2010) 1.78
Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol (2007) 1.73
Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin Exp Metastasis (2009) 1.71
NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett (2010) 1.67
MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer (2010) 1.66
A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther (2009) 1.61
Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J Biol Chem (2010) 1.58
Wnt, hedgehog and snail: sister pathways that control by GSK-3beta and beta-Trcp in the regulation of metastasis. Cell Cycle (2005) 1.57
Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. Pathobiology (2008) 1.47
Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma. Clin Cancer Res (2009) 1.43
The Wnt signal transduction pathway in stem cells and cancer cells: influence on cellular invasion. Stem Cell Rev (2007) 1.41
Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res (2010) 1.38
Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. J Biol Chem (2011) 1.35
Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. J Biol Chem (2010) 1.33
Hepatocyte-derived Snail1 propagates liver fibrosis progression. Mol Cell Biol (2011) 1.32
Up-regulation of sonic hedgehog contributes to TGF-β1-induced epithelial to mesenchymal transition in NSCLC cells. PLoS One (2011) 1.30
Randomized clinical trials in pancreatic cancer. Surg Oncol Clin N Am (2002) 1.30
Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J Hepatol (2011) 1.30
The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior. Cancer Res (1993) 1.28
Extracellular matrix-mediated membrane-type 1 matrix metalloproteinase expression in pancreatic ductal cells is regulated by transforming growth factor-beta1. Cancer Res (2006) 1.27
A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res (1993) 1.26
Network of WNT and other regulatory signaling cascades in pluripotent stem cells and cancer stem cells. Curr Pharm Biotechnol (2011) 1.24
Cross talk between hedgehog and epithelial-mesenchymal transition pathways in gastric pit cells and in diffuse-type gastric cancers. Br J Cancer (2008) 1.24
Collagen regulation of let-7 in pancreatic cancer involves TGF-β1-mediated membrane type 1-matrix metalloproteinase expression. Oncogene (2010) 1.15
MicroRNAs in solid tumors. J Surg Res (2008) 1.11
Hedgehog and epithelial-mesenchymal transition signaling in normal and malignant epithelial cells of the esophagus. Int J Cancer (2009) 1.07
Integrative genomic analyses of ZEB2: Transcriptional regulation of ZEB2 based on SMADs, ETS1, HIF1alpha, POU/OCT, and NF-kappaB. Int J Oncol (2009) 1.05
Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors. Oncol Rep (2010) 0.93
Cancer stem cells: nature versus nurture. Nat Cell Biol (2010) 0.92
Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in normal pancreas. Cancer Res (1995) 0.90
Extent of surgery affects survival for papillary thyroid cancer. Ann Surg (2007) 4.73
National failure to operate on early stage pancreatic cancer. Ann Surg (2007) 3.65
Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg (2009) 3.07
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 3.03
Laparoscopic versus open left pancreatectomy: can preoperative factors indicate the safer technique? Ann Surg (2011) 2.87
Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer (2007) 2.85
Directing surgical quality improvement initiatives: comparison of perioperative mortality and long-term survival for cancer surgery. J Clin Oncol (2008) 2.74
Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med (2012) 2.62
Lymph node evaluation as a colon cancer quality measure: a national hospital report card. J Natl Cancer Inst (2008) 2.46
Evaluation of surveillance bias and the validity of the venous thromboembolism quality measure. JAMA (2013) 2.31
Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-institutional study. J Gastrointest Surg (2014) 2.15
The influence of resident involvement on surgical outcomes. J Am Coll Surg (2011) 2.12
Use and outcomes of laparoscopic-assisted colectomy for cancer in the United States. Arch Surg (2008) 2.10
Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer (2008) 2.09
Cost-effectiveness of treatment strategies for pancreatic head adenocarcinoma and potential opportunities for improvement. Ann Surg Oncol (2012) 2.08
TGF-β: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst (2014) 2.08
Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy. Oncology (Williston Park) (2010) 2.07
Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw (2011) 2.03
Adherence with postdischarge venous thromboembolism chemoprophylaxis recommendations after colorectal cancer surgery among elderly Medicare beneficiaries. Ann Surg (2014) 1.97
Assessment of pancreatic cancer care in the United States based on formally developed quality indicators. J Natl Cancer Inst (2009) 1.92
Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol (2009) 1.90
Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg (2008) 1.90
A multicenter analysis of distal pancreatectomy for adenocarcinoma: is laparoscopic resection appropriate? J Am Coll Surg (2010) 1.83
Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base. J Clin Oncol (2009) 1.75
Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Cancer (2007) 1.63
Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors. Surgery (2013) 1.62
Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol (2008) 1.60
Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg (2011) 1.59
Using the NCDB for cancer care improvement: an introduction to available quality assessment tools. J Surg Oncol (2009) 1.58
Effect of postoperative complications on adjuvant chemotherapy use for stage III colon cancer. Ann Surg (2013) 1.56
Risk-based selective referral for cancer surgery: a potential strategy to improve perioperative outcomes. Ann Surg (2010) 1.53
Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw (2015) 1.52
In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci U S A (2010) 1.47
Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg (2008) 1.47
A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med (2010) 1.46
Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg (2008) 1.46
Variation in lymph node examination after esophagectomy for cancer in the United States. Arch Surg (2012) 1.46
Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res (2010) 1.46
Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg (2007) 1.44
The role of Surgical Champions in the American College of Surgeons National Surgical Quality Improvement Program--a national survey. J Surg Res (2010) 1.43
The significant role of mast cells in cancer. Cancer Metastasis Rev (2011) 1.42
Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg (2007) 1.41
Effect of body mass index on short-term outcomes after colectomy for cancer. J Am Coll Surg (2008) 1.39
Pancreatic mucinous cystic neoplasm size using CT volumetry, spherical and ellipsoid formulas: validation study. JOP (2014) 1.38
Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res (2010) 1.38
Gastric cancer. J Natl Compr Canc Netw (2010) 1.35
Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. J Biol Chem (2011) 1.35
Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. Biochem J (2012) 1.33
Effect of surgeon training, specialization, and experience on outcomes for cancer surgery: a systematic review of the literature. Ann Surg Oncol (2009) 1.30
Effect of postdischarge morbidity and mortality on comparisons of hospital surgical quality. Ann Surg (2010) 1.30
Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum (2009) 1.29
A prospective single institution comparison of peri-operative outcomes for laparoscopic and open distal pancreatectomy. Surgery (2009) 1.27
Extracellular matrix-mediated membrane-type 1 matrix metalloproteinase expression in pancreatic ductal cells is regulated by transforming growth factor-beta1. Cancer Res (2006) 1.27
Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg (2007) 1.25
Adding days spent in readmission to the initial postoperative length of stay limits the perceived benefit of laparoscopic distal pancreatectomy when compared with open distal pancreatectomy. Am J Surg (2011) 1.25
Surgeons' perceptions of public reporting of hospital and individual surgeon quality. Med Care (2013) 1.22
Adequacy and importance of lymph node evaluation for colon cancer in the elderly. J Am Coll Surg (2007) 1.20
Transforming growth factor-beta 1 promotes matrix metalloproteinase-9-mediated oral cancer invasion through snail expression. Mol Cancer Res (2008) 1.19
Laparoscopic-assisted vs. open colectomy for cancer: comparison of short-term outcomes from 121 hospitals. J Gastrointest Surg (2008) 1.18
Slug is a downstream mediator of transforming growth factor-beta1-induced matrix metalloproteinase-9 expression and invasion of oral cancer cells. J Cell Biochem (2009) 1.18
Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg (2011) 1.17
Validation of new readmission data in the American College of Surgeons National Surgical Quality Improvement Program. J Am Coll Surg (2013) 1.15
Impact of tumor location on nodal evaluation for colon cancer. Dis Colon Rectum (2008) 1.15
Glycosylation broadens the substrate profile of membrane type 1 matrix metalloproteinase. J Biol Chem (2003) 1.14
Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol Cancer (2006) 1.14
Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res (2008) 1.14
Utilization of total thyroidectomy for papillary thyroid cancer in the United States. Surgery (2007) 1.13
Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APCDelta468 mice. Cancer Res (2011) 1.13
Interplay between β1-integrin and Rho signaling regulates differential scattering and motility of pancreatic cancer cells by snail and Slug proteins. J Biol Chem (2012) 1.12
Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation of anchorage-independent growth and invasion of malignant melanoma cells. J Biol Chem (2010) 1.12
Laparoscopic versus open resection of gastric gastrointestinal stromal tumors. Am J Clin Oncol (2012) 1.10
Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination. Cancer Res (2009) 1.10
Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther (2006) 1.09
CASH (Chemotherapy-Associated Steatohepatitis) costs. Ann Surg (2006) 1.06
Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg (2014) 1.06
Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas (2008) 1.05
Effect of hospital type and volume on lymph node evaluation for gastric and pancreatic cancer. Arch Surg (2008) 1.05
Isoform-specific upregulation of palladin in human and murine pancreas tumors. PLoS One (2010) 1.01
MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-β signaling. Mol Cancer Res (2011) 1.00
Impact of adjuvant radiation on survival: a note of caution when using cancer registry data to evaluate adjuvant treatments. Ann Surg Oncol (2007) 1.00
Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer (2010) 1.00
Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 0.99
Does hospital type affect pyloromyotomy outcomes? Analysis of the Kids' Inpatient Database. Surgery (2010) 0.99